News, Deals & Awards

Global law firm Ashurst has advised SYNthesis med chem Pty Limited, an Australian company, on the sale of its 100% equity interest in its wholly-owned subsidiary, SYNthesis med chem (Hong Kong) Limited.  The subsidiary business is a contract research organisation (CRO) carrying out research and development of new preclinical small molecule drugs with operations in China, Australia, UK and US.

The PDF server is offline. Please try after sometime.

Key Contacts

We bring together lawyers of the highest calibre with the technical knowledge, industry experience and regional know-how to provide the incisive advice our clients need.

Keep up to date

Sign up to receive the latest legal developments, insights and news from Ashurst.  By signing up, you agree to receive commercial messages from us.  You may unsubscribe at any time.

Sign up
Get Started

        Forgot Password - Ashurst Account

        If you have forgotten your password, you can request a new one here.


        Forgot password? Please contact your relationship manager to find out more about our client portal.
        Ashurst Loader